RE:RE:ASCO June 3-7For phase Ia results there is no need to wait for a conference presentation to disclose the important data, if they have good data. A press release can give the key data, then they could do another KOL presentation, like they did last year, this time giving more in depth data and explainations about the data and how it leads positively to phase Ib. Unless they have some spectacular results on one or two patients, I don't think that phase Ia results will lead to a big rise in the SP. But solid overall data well linked together, relation between PK/PD data, toxicity and sortilin expression, stuff like that, and some mild efficacy data, stable disease and maybe small tumor regression.
I think the hope with phase Ia results should be that it strongly hints at a proof of concept, without having it as a certainty. In other words, we need to come out of phase Ia with more positive elements leading to think that TH1902 will work when used at the right dose on the right patients, for a sufficient number of cycles.
Wino115 wrote: You're right that the annual is early June, so likely way too soon to present unless they are basically finished now and putting data and analysis together (but we haven't been told MTD). Looks like maybe there's a few associated ones and a gynecological one in Spain (how nice).
- 2022 American Society of Clinical Oncology (ASCO) Annual Meeting CME Must Attend
June 03-07, 2022 | Chicago, IL, United States
- Pancreas and Related Cancers: What is New in 2022? CME
June 03, 2022 | Philadelphia, PA, United States
- 20th International Symposium on Pediatric Neuro-Oncology (ISPNO) and the Annual Meeting of the Brain...
June 11-15, 2022 | Hamburg, Germany
- ESMO Gynaecological Cancers Congress CME
June 17-18, 2022 | Valencia, Spain
- Oncology Updates with ASCO Highlights 2022 CME
June 18, 2022 | Saint Louis, MO, United States
- ASCO Direct™ Highlights: 2022 Official Annual Meeting Review CME
June 18-19, 2022 | Seattle, WA, United States
- EORTC-ESMO-AACR Workshop on Methods in Clinical Cancer Research (MCCR)
June 18-24, 2022 | Sint-Michielsgestel, Netherlands
- Liquid Biopsy for Cancer
June 19-24, 2022 | South Hadley, MA, United States
- European Association for Cancer Research (EACR) 2022 Congress: Innovative Cancer Science: Translatin...
June 20-23, 2022 | Sevilla, Spain
- Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Applicatio... CME
June 23-26, 2022 | Boston, MA, United States
SPCEO1 wrote: I thought the ASCO conference (finally remembered the name of it) was in late June but it is actually in early June. So, a late breaker presentation there would certainly fit from a timing prespective but there might not be enough time to pull that off. I also wonder how often a phase 1a would be even considered for a late breaker - probably not too often I would imagine. They may be hustling just to get any data put together for this conference. But if they can pull it off, we will not have to wait as long as I thought we would to hear any good news they share about phase 1a data.